Literature DB >> 32505357

DUSP4 is involved in the enhanced proliferation and survival of DUSP4-overexpressing cancer cells.

Praphasawat Ratsada1, Naoki Hijiya2, Shinya Hidano3, Yoshiyuki Tsukamoto1, Chisato Nakada4, Tomohisa Uchida1, Takashi Kobayashi3, Masatsugu Moriyama1.   

Abstract

Dual-specificity phosphatase 4 (DUSP4), a MAP kinase phosphatase, has been regarded as a tumor suppressor gene in several cancers. However, high-level expression of DUSP4 is occasionally observed in specific cancers and its functional significance in carcinogenesis is not fully understood. In the present study, we showed that downregulation of DUSP4 suppressed the proliferation of cancer cell lines exhibiting high expression of DUSP4 by inducing apoptosis and cell cycle arrest at G2/M phase. Expression microarray analyses and pathway analyses revealed that downregulation of DUSP4 activated the p53 signaling pathway, and might be involved in cell growth suppression. Aberrant accumulation of p53 and induction of p53 downstream target genes were further investigated. Furthermore, cell growth suppression following downregulation of DUSP4 was markedly attenuated in p53-deleted cells established using the CRISPR/Cas9 system. These findings suggest that constitutive expression of DUSP4 in cancer cells contributes to enhanced proliferation through escape from apoptosis and cell cycle arrest. We propose that DUSP4 could be a novel therapeutic target for cancers overexpressing it.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cell cycle arrest; DUSP4; Proliferation; p53 signaling pathway

Year:  2020        PMID: 32505357     DOI: 10.1016/j.bbrc.2020.05.140

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance.

Authors:  Zahra Zandi; Bahareh Kashani; Zivar Alishahi; Atieh Pourbagheri-Sigaroodi; Fatemeh Esmaeili; Seyed H Ghaffari; Davood Bashash; Majid Momeny
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-04       Impact factor: 4.553

2.  ASCL2 Affects the Efficacy of Immunotherapy in Colon Adenocarcinoma Based on Single-Cell RNA Sequencing Analysis.

Authors:  Lei Wu; Shengnan Sun; Fei Qu; Xiuxiu Liu; Meili Sun; Ying Pan; Yan Zheng; Guohai Su
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

3.  DUSP4 Silencing Enhances the Sensitivity of Breast Cancer Cells to Doxorubicin through the Activation of the JNK/c-Jun Signalling Pathway.

Authors:  Mashael S Al-Mutairi; Hany O Habashy
Journal:  Molecules       Date:  2022-09-20       Impact factor: 4.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.